Supplementary Table 2.
The characteristics of antihypertensive at baseline and 6 months
| Clinical trials | Number of drugs at baseline (R/C) | Number of drugs at 6 months (R/C) | Rate of drugs change (R/C) | Antihypertensive drug classes and their distribution at baseline | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACEI or ARB (R/C) | ACEI (R/C) | ARB (R/C) | CCB (R/C) | Diuretics (R/C) | Aldosterone antagonist (R/C) | β-blocker (R/C) | Direct renin inhibitors (R/C) | α-blocker (R/C) | Centrally acting sympatholytics (R/C) | Vasodilators (R/C) | ||||
| DENERHTN | 3/3 | 5.3/5.4 | - (-/-) | 100/100 | -/- | -/- | 100/100 | 100/100 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 |
| DENERVHTA | 4.3/3.9 | -/- | 29 (27/30) | 100/92 | -/- | -/- | 100/100 | 91/69 | 0/0 | 55/77 | 0/0 | 55/39 | 18/8 | 0/0 |
| OSLO | 5.1/5.0 | 4.9/5.2 | 31.5 (11.1/50.0) | 100/100 | -/- | -/- | 100/100 | 89/70 | 33/60 | 56/90 | 22/0 | 56/20 | 56/40 | 0/20 |
| Prague-15 | 5.1/5.4 | 5.0/5.6 | -(-/-) | 100/100 | 89/89 | -/- | -/- | 100/100 | 27/24 | 66/69 | 0/0 | 54/46 | 54/61 | 0/0 |
| ReSET | 4.1/4.2 | 4.1/4.2 | 39 (46/33) | 53/45 | 53/45 | 0/0 | 86/85 | 53/85 | 61/61 | 81/76 | 3/6 | 11/22 | 17/6 | 0/0 |
| SYMPLICITY-FLEX | 4.4/4.3 | -/- | 21 (-/-) | -/- | 51/56 | 46/47 | 69/64 | 100/92 | 3/6 | 91/94 | 3/8 | 21/14 | 26/28 | 6/11 |
| SYMPLICITY HTN-Japan | 4.9/4.9 | 4.9/4.9 | 7.3 (9.1/5.3) | -/- | 9.1/15.8 | 100/94.7 | 95.5/94.7 | 100/100 | 45.5/36.8 | 81.8/68.4 | 0/0 | 22.7/42.1 | 0/0 | 0/0 |
| SYMPLICITY HTN-2 | 5.2/5.3 | -/- | 13 (20.4/5.9) | 96/94 | -/- | -/- | 79/83 | 89/91 | 17/17 | 83/69 | 0/0 | 33/19 | 52/52 | 15/17 |
| SYMPLICITY HTN-3 | 5.1/5.2 | 5.0/5.2 | 39 (-/-) | -/- | 49.2/41.5 | 50.0/53.2 | 69.8/73.1 | 99.7/100 | 22.5/28.7 | 85.2/86.0 | 7.1/7.0 | 11.0/13.5 | 49.2/43.9 | 36.8/45 |
ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin II receptor blocker; C: Control group; CCB: Calcium channel blockers; R: Renal denervation group.